PharmaCyte Biotech, Inc.

- 30 DEC 2015
PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today a shareholder update on PharmaCyte’s pancreatic cancer and diabetes programs. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, highlighted the
Read more →
- Posted in
- News
- 15 DEC 2015
PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media
Read more →
- Posted in
- News
- 07 DEC 2015
PharmaCyte Biotech Provides Update on Malignant Ascites and New Colon Cancer Studies
SILVER SPRING, Md., Dec. 07, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today issued an update on the preclinical studies that are designed to determine the effectiveness of the Cell-in-a-Box® plus ifosfamide therapy
Read more →
- Posted in
- News
- 04 DEC 2015
PharmaCyte Contractor Chamow & Associates to Visit Cell-in-a-Box® Encapsulation Facility in Bangkok, Thailand
SILVER SPRING, Md., Dec. 04, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that representatives from Chamow & Associates, the San Francisco Bay Area firm contracted to assist PharmaCyte in preparing the
Read more →
- Posted in
- News
- 24 NOV 2015
PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment
SILVER SPRING, Md., Nov. 24, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the European Commission has updated its website to reflect that PharmaCyte Biotech Europe Limited, a subsidiary of PharmaCyte
Read more →
- Posted in
- News
- 19 NOV 2015
PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board
SILVER SPRING, MD, November 19, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Prof. Hans-Peter Hammes, M.D., has accepted an appointment to PharmaCyte’s Scientific Advisory Board. Prof. Hammes is recognized
Read more →
- Posted in
- News
- 17 NOV 2015
PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment
SILVER SPRING, Md., Nov. 17, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that, upon the recommendation of the European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation
Read more →
- Posted in
- News
- 11 NOV 2015
PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center
SILVER SPRING, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that Manuel Hidalgo, MD, PhD, an internationally respected oncologist and a member of PharmaCyte ’s Scientific Advisory Board, has
Read more →
- Posted in
- News
- 23 OCT 2015
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
SILVER SPRING, MD, October 23, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr.
Read more →
- Posted in
- News
- 21 OCT 2015
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
SILVER SPRING, Md., Oct. 21, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte’s treatment (Cell-in-a-Box®
Read more →
- Posted in
- News

Press Releases